Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amphotericin b
Drug ID BADD_D00132
Description Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.
Indications and Usage Used to treat potentially life threatening fungal infections.
Marketing Status Prescription; Discontinued
ATC Code A01AB04; A07AA07; G01AA03; J02AA01
DrugBank ID DB00681
KEGG ID D00203
MeSH ID D000666
PubChem ID 14956
TTD Drug ID D02DWM
NDC Product Code 38779-0191; 63622-0125; 63622-0123; 65044-7183; 51552-0304; 51927-1726; 45932-0008; 55500-0001; 63622-0124; 62991-1173; 62756-233; 39822-1055; 0469-3051
Synonyms Amphotericin B | Amphotericin | Fungizone | Amphotericin B Cholesterol Dispersion | Amphotericin B Colloidal Dispersion | Amphocil
Chemical Information
Molecular Formula C47H73NO17
CAS Registry Number 1397-89-3
SMILES CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O) O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cell deathMacrophage migration inhibitory factorP14174T39977Not Available
Cell deathD-dopachrome decarboxylaseP30046Not AvailableNot Available
NeurotoxicityTumor necrosis factorP01375T20178Not Available
NeurotoxicityInterleukin-1 alphaP01583T16340Not Available
NeurotoxicityNitric oxide synthase, inducibleQ06518Not AvailableNot Available
NeurotoxicityInterferon gammaP01579T77664Not Available
NeurotoxicityNuclear factor NF-kappa-B p105 subunitP19838T40192Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain lower07.01.05.0100.000412%Not Available
Abdominal pain upper07.01.05.003--
Acidosis14.01.03.002--
Acne23.02.01.001--Not Available
Acute hepatic failure09.01.03.001--Not Available
Acute myeloid leukaemia16.01.05.001; 01.10.05.0010.000161%Not Available
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.01.0030.000618%
Albuminuria20.02.01.001--Not Available
Alopecia23.02.02.001--
Alveolitis allergic22.01.01.002; 10.01.03.008--Not Available
Amblyopia06.02.01.001--Not Available
Amylase increased13.05.01.009--
Anaemia01.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.0010.001030%
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angioedema10.01.05.009; 23.04.01.001--Not Available
Anorectal disorder07.03.01.001--Not Available
Anuria20.01.03.002--Not Available
Anxiety19.06.02.002--
Apnoea22.02.01.001--
Application site pain12.07.01.004; 08.02.01.004--Not Available
Arrhythmia02.03.02.0010.000108%Not Available
Arthralgia15.01.02.001--
Ascites09.01.05.003; 07.07.01.001; 02.05.04.0020.000412%
The 1th Page    1 2 3 4 5    Next   Last    Total 13 Pages